Madrigal Pharmaceuticals reported a 127 percent [1] increase in revenue during the first quarter of 2026, driven by sales of its drug Rezdiffra.
This growth signals a rapid market adoption of the first approved therapy for metabolic dysfunction-associated steatohepatitis (MASH), a condition with significant unmet medical needs. The company is now leveraging this financial momentum to pivot from a single-product firm to a broader therapeutic franchise.
William Sibold, CEO of Madrigal Pharmaceuticals, said the company ended its first full year on the market with nearly $1 billion [2] in net sales. He said these results solidified Rezdiffra as the foundational therapy in MASH.
To sustain this growth, the company announced a global licensing agreement on Feb. 11, 2026 [4]. Madrigal acquired exclusive rights to six [4] pre-clinical siRNA programs from Suzhou Ribo Life Science Co. Ltd., a firm based in China. These genetic approaches are intended to diversify the company's pipeline beyond its current offerings.
The expansion comes as the broader U.S. MASH market has grown nearly 50 percent [2] since the end of 2023. By incorporating siRNA technology, Madrigal aims to address the disease through multiple biological pathways, a strategy designed to capture a larger share of the expanding patient population.
Headquartered in Conshohocken, Pennsylvania, the company continues to focus on the rapid scaling of Rezdiffra while transitioning its research and development toward these new licensed programs [4].
“Madrigal Pharmaceuticals reported a 127 percent increase in revenue during the first quarter of 2026”
Madrigal's aggressive expansion into siRNA technology indicates a strategic shift to protect its market lead. By licensing multiple pre-clinical programs while Rezdiffra is at its peak growth, the company is attempting to build a 'moat' around its MASH franchise to prevent competitors from capturing the rapidly growing patient base in the U.S.
